EC Number   |
Application |
Reference |
|---|
   2.7.12.1 | analysis |
development of a protein chip consisting of a silicone elastomer microwell array with recombinant enzyme covalently attached to the wells via a 3-glycidoxypropyltrimethoxysilane crosslinker for large scale activity assay, overview |
662926 |
| 2.7.12.1 | diagnostics |
DYRK1A is a risk factor for Alzheimer's disease, enabling detection of the disease prior to the development of behavioural symptoms by analyzing human plasma |
739790 |
| 2.7.12.1 | diagnostics |
enzyme DYRK2 expression is an independent prognostic factor and can be used as a prognostic biomarker of human colorectal cancer |
741257 |
| 2.7.12.1 | diagnostics |
the enzyme can act as a bona fide biomarker for liver cancer with prognostic significance in a large cohort of liver cancer patients |
741425 |
| 2.7.12.1 | drug development |
the enzyme is a target in drug development for treatment of Alzheimer's disease |
740550 |
| 2.7.12.1 | medicine |
DYRK1A controls cyclin L2 expression, leading to restriction of HIV replication in macrophages |
761772 |
| 2.7.12.1 | medicine |
Dyrk1B may serve as a target for therapy in human papillomavirus-associated cancers |
741084 |
| 2.7.12.1 | medicine |
DYRK2 phosphorylates Notch1-IC in response to chemotherapeutic agents and facilitates its proteasomal degradation by FBXW7 ubiquitin ligase through a Thr-2512 phosphorylation-dependent mechanism. DYRK2 regulation by chemotherapeutic agents has a relevant effect on the viability, motility and invasion capacity of cancer cells expressing NOTCH1 |
760846 |
| 2.7.12.1 | medicine |
expression of DYRK2 can be a favorable prognostic marker in pulmonary adenocarcinoma |
705413 |
| 2.7.12.1 | medicine |
involvement of early onset tauopathy in individuals with Down syndrome, research and development of therapeutics for tauopathies |
693148 |
